Cite
HARVARD Citation
Baird, R. et al. (2021). First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Journal of clinical oncology. 39 (2), pp. 145-154. [Online].